IUPAC/Chemical Name
(S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-2-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2R,3R,6S)-3-amino-6-(aminomethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide
InChi Key
MKKYBZZTJQGVCD-XTCKQBCOSA-N
InChi Code
1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1
SMILES Code
O1[C@H](O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@H]2O[C@@H](CC[C@H]2N)CN)N)NC([C@H](CCN)O)=O)[C@H](O)[C@H]([C@@H]([C@H]1CO)O)N
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
552.63
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Hwang JH, Lee JH, Kim JS, Hwang JH, Lee CS. Arbekacin as an Alternative Drug to Teicoplanin for the Treatment of MRSA Infection. Yonsei Med J. 2016 Jul;57(4):1047-8. doi: 10.3349/ymj.2016.57.4.1047. PubMed PMID: 27189305; PubMed Central PMCID: PMC4951450.
2: Lee JH, Lee CS. Clinical Usefulness of Arbekacin. Infect Chemother. 2016 Mar;48(1):1-11. doi: 10.3947/ic.2016.48.1.1. Epub 2016 Mar 31. Review. PubMed PMID: 27104010; PubMed Central PMCID: PMC4835429.
3: Miura K, Nakagawa M, Takahashi H, Uchino Y, Kodaira H, Iriyama N, Sakagami M, Ohtake S, Kobayashi S, Hojo A, Kurita D, Kobayashi Y, Kusuda M, Hirabayashi Y, Hatta Y, Takei M. Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies. Int J Hematol. 2016 Mar;103(3):334-40. doi: 10.1007/s12185-015-1926-6. Epub 2015 Dec 29. PubMed PMID: 26715149.
4: Hwang JH, Lee JH, Hwang JH, Chung KM, Lee EJ, Yoon YJ, Moon MK, Kim JS, Won KS, Lee CS. Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus. J Korean Med Sci. 2015 Jun;30(6):688-93. doi: 10.3346/jkms.2015.30.6.688. Epub 2015 May 13. PubMed PMID: 26028918; PubMed Central PMCID: PMC4444466.
5: Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother. 2015;59(6):3263-70. doi: 10.1128/AAC.04839-14. Epub 2015 Mar 23. PubMed PMID: 25801559; PubMed Central PMCID: PMC4432132.
